Cardiovasc Diabetol. 2025 Apr 2;24(1):152. doi: 10.1186/s12933-025-02701-z.ABSTRACTBACKGROUND: Disruption of lipid metabolism contributes to increased cardiovascular risk in diabetes.METHODS: We evaluated the associations between serum lipidomic profile and subclinical carotid atherosclerosis (SCA)
Cardiovasc Diabetol. 2025 Apr 2;24(1):150. doi: 10.1186/s12933-025-02712-w.ABSTRACTBACKGROUND: The triglyceride-glucose (TyG) index is recognized as an indicator of insulin resistance and is linked to cardiovascular disease (CVD) in patients with type 2 diabetes. However, its utility in patients wit
Cardiovasc Diabetol. 2025 Apr 2;24(1):151. doi: 10.1186/s12933-025-02704-w.ABSTRACTBACKGROUND: The purpose of this study was to explore the incremental predictive value of liver fat fraction (LFF) in forecasting major adverse cardiovascular events (MACE) among patients with type 2 diabetes mellitus
Cardiovasc Diabetol. 2025 Mar 29;24(1):146. doi: 10.1186/s12933-025-02696-7.ABSTRACTOBJECTIVE: To evaluate the efficacy of anti-CD3 monoclonal antibody (mAb) in patients with type 1 diabetes (T1D) and identify the influencing factors.METHODS: Randomized controlled trials comparing anti-CD3 mAb with
Cardiovasc Diabetol. 2025 Mar 29;24(1):145. doi: 10.1186/s12933-025-02698-5.ABSTRACTBACKGROUND: The effect of cadmium exposure on mortality risk among individuals with diabetes and prediabetes remains unclear, particularly regarding potential mediation by oxidative stress and inflammation. This stud
Cardiovasc Diabetol. 2025 Mar 28;24(1):144. doi: 10.1186/s12933-025-02666-z.ABSTRACTCardiovascular Autonomic Neuropathy (CAN) is one of the most devastating complications of Diabetes Mellitus (DM) and presents high morbidity and mortality. Its association with diabetic kidney disease (DKD) worsens t
Cardiovasc Diabetol. 2025 Mar 28;24(1):143. doi: 10.1186/s12933-025-02694-9.ABSTRACTBACKGROUND: Pericoronary adipose tissue attenuation (PCATa), derived from coronary computed tomography angiography (CCTA), is a novel marker of inflammation in the coronary arteries. Patients with type 2 diabetes mel
Cardiovasc Diabetol. 2025 Mar 26;24(1):139. doi: 10.1186/s12933-025-02685-w.ABSTRACTBACKGROUND: Understanding the relationship between serum ferritin levels and cardiovascular outcomes in type 2 diabetes is crucial for improving risk stratification and guiding therapeutic interventions aimed at prev
Cardiovasc Diabetol. 2025 Mar 26;24(1):141. doi: 10.1186/s12933-025-02699-4.ABSTRACTBACKGROUND: Heart failure (HF) is increasingly recognized as a heterogeneous cardiometabolic disorder, often in the context of overweight/obesity independently from diabetes. Sodium-glucose cotransporter-2 inhibitors
Cardiovasc Diabetol. 2025 Mar 26;24(1):142. doi: 10.1186/s12933-025-02686-9.ABSTRACTOBJECTIVE: C-reactive protein-triglyceride-glucose index (CTI) has been proposed as a novel biomarker for insulin resistance and inflammation. However, the association between CTI and the risk of stroke, particularly
Cardiovasc Diabetol. 2025 Mar 26;24(1):140. doi: 10.1186/s12933-025-02665-0.ABSTRACTBACKGROUND: The prevalence of early-onset type 2 diabetes (EOD) is rapidly increasing. This study intends to screen for early cardiovascular abnormalities in patients newly diagnosed with EOD and evaluate the cardiov
Cardiovasc Diabetol. 2025 Mar 22;24(1):134. doi: 10.1186/s12933-025-02688-7.ABSTRACTBACKGROUND: Heart failure (HF) with preserved ejection fraction (HFpEF) is increasingly prevalent worldwide due to aging and comorbidities. Epicardial adipose tissue (EAT), favored by diabetes and obesity, was shown
Cardiovasc Diabetol. 2025 Mar 22;24(1):136. doi: 10.1186/s12933-025-02659-y.ABSTRACTBACKGROUND: Mineralocorticoid receptor antagonists (MRAs) are often underutilized in patients with heart failure (HF), particularly those with diabetes and/or chronic kidney disease (CKD). However, the impact of conc
Cardiovasc Diabetol. 2025 Mar 21;24(1):131. doi: 10.1186/s12933-025-02687-8.ABSTRACTBACKGROUND: The triglyceride-glucose index serves as a dependable biomarker for gauging insulin resistance linked to cardiovascular disease. Our study was designed to investigate how the trajectory of the triglycerid
Cardiovasc Diabetol. 2025 Mar 21;24(1):133. doi: 10.1186/s12933-025-02693-w.ABSTRACTBACKGROUND: Although some studies have examined the association between the triglyceride glucose-body mass index (TyG-BMI) and cardiovascular outcomes in the cardio-renal-metabolic (CRM) background, none have explore
Cardiovasc Diabetol. 2025 Mar 21;24(1):130. doi: 10.1186/s12933-025-02676-x.ABSTRACTBACKGROUND: The guidelines provided by the World Health Organization (WHO) recommend a minimum of 150 min/week of moderate-to-vigorous physical activity (MVPA) for optimal overall health benefits. However, it remains
Cardiovasc Diabetol. 2025 Mar 20;24(1):129. doi: 10.1186/s12933-025-02691-y.ABSTRACTBACKGROUND: Diabetes mellitus (DM) has been shown to increase the rate of aortic stenosis (AS) progression. However, the impact of impaired plasma glucose on valvular calcification remains poorly understood. Using ex
Cardiovasc Diabetol. 2025 Mar 20;24(1):127. doi: 10.1186/s12933-025-02625-8.ABSTRACTOBJECTIVE: Increasing evidence highlights the critical role of Piezo1 in cardiovascular diseases, with its expression upregulated in diabetic heart. However, the involvement of Piezo1 in the pathogenesis of diabetic
Cardiovasc Diabetol. 2025 Mar 20;24(1):125. doi: 10.1186/s12933-025-02645-4.ABSTRACTBACKGROUND: This study aims to identify early metabolomic biomarkers of gestational diabetes mellitus (GDM) and evaluate their association with hepatic steatosis.METHODS: We compared maternal serum metabolomic profil
No abstractCardiovasc Diabetol. 2025 Mar 15;24(1):122. doi: 10.1186/s12933-025-02663-2.NO ABSTRACTPMID:40089685 | PMC:PMC11909880 | DOI:10.1186/s12933-025-02663-2
Cardiovasc Diabetol. 2025 Mar 14;24(1):120. doi: 10.1186/s12933-025-02670-3.ABSTRACTEmerging evidence reveals a complex association between type 2 diabetes (T2D) and coronary heart disease (CHD), which share common risk factors and biological pathways. This study aims to identify the shared proteomi
Cardiovasc Diabetol. 2025 Mar 12;24(1):117. doi: 10.1186/s12933-024-02561-z.ABSTRACTOBJECTIVE: To investigate standardized incidence of atrial fibrillation (AF) in individuals with type 1 diabetes (T1DMM) compared with matched controls from the general population. Additionally, to examine optimal le
Cardiovasc Diabetol. 2025 Mar 10;24(1):113. doi: 10.1186/s12933-025-02669-w.ABSTRACTBACKGROUND: Although existing studies have reported associations between blood group A and cardiometabolic diseases (CMD), most have focused on dominant inheritance models. However, genome-wide association studies ha
Cardiovasc Diabetol. 2025 Mar 10;24(1):115. doi: 10.1186/s12933-025-02671-2.ABSTRACTBACKGROUND: The triglyceride glucose index (TyG index) is a marker of insulin resistance linked to the incidence of major adverse cardiovascular events (MACE) in diverse populations. However, its long-term prognostic
